section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Enzyme Inhibitors (CYP2D6):


* Propoxyphene (Darvon) was withdrawn from the US market.


Comment:

Thioridazine can prolong the QT interval. Inhibitors of CYP2D6 may increase the risk of ventricular arrhythmias such as torsades de pointes. The product information for thioridazine states that concurrent use with known CYP2D6 inhibitors (or fluvoxamine) is contraindicated. Note that because terbinafine has an extraordinarily long terminal half-life, the inhibitory effect of terbinafine on CYP2D6 may last for many weeks after terbinafine is discontinued.


Class 2: Use Only if Benefit Felt to Outweigh Risk